Search results for "ONCOLOGIA"

showing 10 items of 386 documents

Aportación de la radioterapia guiada por la imagen al tratamiento del cáncer de próstata

2010

Objetivo: Demostrar que la verificación mediante Cone Beam CT (CBCT) en una serie de pacientes tratados con radioterapia externa 3D (RTE3D) por su cáncer de próstata (CP) se relaciona con una reducción de los niveles de toxicidad aguda y tardía. Material y Métodos: Se ha realizado un estudio retrospectivo no aleatorizado de 2 grupos homogéneos de pacientes tratados entre 2005 y 2008, 46 pacientes verificados mediante Electronic Portal Devices (EPIC) y 48 verificados mediante CBCT (Electa Synergy), con una mediana de edad de 67 años (42-85 años). Recibieron RTE3D por CP estadio localizado ( T1-T3b N0 M0 ), prescribiéndose las mismas dosis, simulados y planificados con los mismos criterios y …

616.6Facultat de Medicina616617Patologia. Medicina clínica. OncologiaPatologia del sistema genitourinariCirurgia. Ortopèdia. Oftalmologia
researchProduct

Ni herois ni víctimes. Representació social del càncer i dels malalts de càncer

2012

Les representacions socials del malalt oncològic proporcionen les nocions i les teories que fan estables i eficaces les relacions que estableix amb el seu entorn. Aquest procés té repercussions en l'estigmatització i la categorització dels malalts oncològics que sovint són vistos i es veuen a si mateixos com a víctimes o com a herois. Tanmateix, malgrat la rellevància del problema en la psicologia social, són pocs els estudis que s'han preocupat d'analitzar- lo. El present article té per objecte l'anàlisi de la representació social del càncer i del malalt oncològic en la població espanyola. Amb aquest fi utilitza associacions lliures i preguntes obertes realitzades a una mostra de dos-cents…

:PSICOLOGÍA [UNESCO]UNESCO::PSICOLOGÍARepresentacions socials oncologia personal sanitari i càncer. Social representations oncology sanitary personnel and cancer. Artículo
researchProduct

Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma

2012

Oral metronomic chemotherapy is a therapeutic option which is particularly attractive due to its ease of administration and low toxic burden. Its mechanism of action probably involves antiangiogenetic effect rather than a classical antiproliferative effect like standard maximally tolerated dose-based regimens.A retrospective analysis of 61 patients with advanced breast carcinoma was carried out with the aim of reporting activity in terms of response rate, control of tumor-related symptoms, outcome, and toxicity. All patients had hormonal therapy-resistant metastatic disease and had previously received two lines of chemotherapy. The first cohort of 22 patients received oral cyclophosphamide …

AdultAged 80 and overAntineoplastic Combined Chemotherapy ProtocolNeoplasms Hormone-DependentSettore MED/06 - Oncologia MedicaPalliative CareAdministration OralBreast NeoplasmsMiddle AgedDisease-Free SurvivalDrug Administration ScheduleCohort StudiesMethotrexateAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleCohort StudieAntineoplastic Agents AlkylatingCyclophosphamideBreast NeoplasmAgedHumanNeoplasm StagingRetrospective Studies
researchProduct

Emotional expression and coping style in female breast cancer.

2007

Background: The study of the relationship of emotional status and tumor etiology has been investigated in order to elaborate a multifactorial model able to provide an answer integrating the different disciplines on cancer. The aim of this work is to investigate the knowledge on the alexithymia construct, exploring the presence of such trait in women affected by mammary carcinoma and analyzing the used coping strategies. The study has also examined personal thoughts related to event control (locus of control). Method: The Toronto Alexithymia Scale, Coping Orientation to Problems Experienced, and Locus of Control questionnaires were administered to a group of 86 women aged 31-55 years (mean =…

AdultCoping (psychology)medicine.medical_specialtySettore MED/06 - Oncologia Medicabreast cancer psychological aspectDysfunctional familyBreast NeoplasmsToronto Alexithymia ScaleBreast cancerAlexithymiaAdaptation PsychologicalMedicineHumansEmotional expressionAffective Symptomsmedicine.diagnostic_testbusiness.industrySettore M-PSI/03 - PsicometriaHematologyMiddle Agedmedicine.diseaseSurgeryExpressed EmotionLocus of controlOncologyEtiologyFemalebusinessClinical psychology
researchProduct

Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis

2020

Non-alcoholic fatty liver disease (NAFLD) is becoming the main cause of liver disease in Western countries, especially in morbidly obese patients (MOPs). The proprotein convertase subtilisin/kexin type 9 (PCSK9) has been recently studied because of its possible involvement in the pathogenesis of NAFLD, but its role, at least in MOPs, is still controversial. The aim of this study was to clarify the correlation between the circulating levels of the PCSK9 protein (cPCSK9) and its hepatic expression with the severity of liver damage in a population of MOPs with NAFLD undergoing bariatric surgery. PCSK9 mRNA was positively correlated with FASN, PPARγ and PPARα mRNAs, while no significant differe…

AdultMale0301 basic medicinemedicine.medical_specialtySettore MED/06 - Oncologia MedicaPopulationBariatric SurgeryInflammation030204 cardiovascular system & hematologySeverity of Illness IndexPathogenesisNon-alcoholic fatty liver disease (NAFLD)03 medical and health sciencesBallooning degenerationLiver disease0302 clinical medicineInternal medicinemedicineHumansMorbidly obese patients (MOPs)educationMolecular Biologyeducation.field_of_studybusiness.industryPCSK9Fatty liverCell BiologyMiddle AgedLipid Metabolismmedicine.diseaseObesity MorbidFatty LiverProprotein convertase subtilisin/kexin type 9 (PCSK9)030104 developmental biologyEndocrinologyLiverFemaleProprotein Convertase 9medicine.symptomSteatosisbusiness
researchProduct

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorecta…

2009

BACKGROUND: The aim of the current study was the investigation of the value of bevacizumab + 5-fluorouracil(5–FU)/folinic acid in patients with advanced colorectal cancers who have exhausted standard chemotherapy options. METHODS: The authors included 48 heavily pretreated patients (colon:rectum, 33:15; men:women, 23:25; median age, 63 years; range, 27-79 years) whose disease had progressed during or within an oxaliplatin-based first-line chemotherapy, an irinotecan-based second-line regimen, and a third-line treatment with cetuximab plus weekly irinotecan. Bevacizumab was given at a dose of 5 mg/kg. 5-FU/folinic acid was administered according to the de Gramont schedule. RESULTS: The respo…

AdultMaleCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerSettore MED/06 - Oncologia MedicaLeucovorinCetuximabAntibodies Monoclonal HumanizedGastroenterologyDrug Administration ScheduleFolinic acidInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAgedCetuximabbusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseSurgeryOxaliplatinIrinotecanBevacizumabRegimenBevacizumabcolorectal cancerOncologyDrug Resistance NeoplasmRetreatmentFemaleFluorouracilbusinessBevacizumab; Colorectal cancer; cancer combination chemotherapyColorectal Neoplasmsmedicine.drug
researchProduct

High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression

2013

Tryptase(+) mast cells (MCs), abundant in the invasive front of tumours, contribute to tissue remodelling. Indeed, protease-activated receptor- 2 (PAR-2) activation by MC-tryptase is considered an oncogenic event in colorectal cancer (CRC). Recently, we have suggested NHERF1 as a potential new marker in CRC. In this study, we aimed to determine the distribution of tryptase(+) MCs and PAR-2 and to examine the relationship between PAR-2 and NHERF1, investigating their reputed usefulness as tumour markers. We studied a cohort of 115 CRC specimens including primary cancer (C) and adjacent normal mucosa (NM) by immunohistochemical double staining, analyzing the protein expression of MC-tryptase,…

AdultMaleCytoplasmPathologymedicine.medical_specialtySodium-Hydrogen ExchangersColorectal cancerLymphovascular invasionSettore MED/06 - Oncologia MedicainvasivenesstryptasePAR-2Cell CountTryptaseModels BiologicalImmunophenotypingNHERF1Intestinal mucosamedicineHumansReceptor PAR-2Mast CellsIntestinal Mucosaprognostic factorProtease-activated receptor 2AgedAged 80 and overbiologyColorectal cancer PAR-2 mast cell tryptase NHERF1 prognostic factor invasiveness aggressivenessOriginal ArticlesCell BiologyaggressivenessMiddle AgedPhosphoproteinsPrognosismedicine.diseaseMast cellColorectal cancermedicine.anatomical_structurebiology.proteinMolecular MedicineImmunohistochemistryFemaleTryptasesmast cellColorectal Neoplasms
researchProduct

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter p…

2010

Adrenocortical carcinoma (ACC) is a rare neoplasm characterized by poor prognosis. First-line systemic treatments in advanced disease include mitotane, either alone or in combination with chemotherapy. Studies evaluating second-line therapy options have obtained disappointing results. This trial assessed the activity and toxicity of gemcitabine plus metronomic fluoropyrimidines in heavily pretreated advanced ACC patients. From 1998 to 2008, 28 patients with advanced ACC progressing after mitotane plus one or two systemic chemotherapy lines were enrolled. They received a combination of i.v. gemcitabine (800 mg/m2, on days 1 and 8, every 21 days) and i.v. 5-fluorouracil protracted infusion (2…

AdultMaleMucositisOncologyAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyAdrenocortical carcinomaSettore MED/06 - Oncologia MedicaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhases of clinical researchDeoxycytidineGastroenterologyDrug Administration ScheduleCapecitabineEndocrinologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineMucositisHumansMitotaneCapecitabineAgedChemotherapybusiness.industryLeukopeniaMiddle Agedmedicine.diseaseThrombocytopeniaGemcitabineAdrenal Cortex NeoplasmsGemcitabineRegimenTreatment OutcomeOncologyFluorouracilDisease ProgressionFemaleFluorouracilbusinessmedicine.drug
researchProduct

Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma

2013

Background: Neutropenia and its complications represent one of the principal dose-limiting toxicity issues in chemotherapeutic regimens for soft tissue sarcoma. Prophylactic granulocyte colony-stimulating factor (G-CSF) reduces the risk of febrile neutropenia (FN). The correct timing of G-CSF administration should be considered in order to optimize the prophylactic treatment. Patients and Methods: Patients (≥18 years old) affected by soft tissue sarcoma and treated with epirubicin and ifosfamide, underwent prophylactic treatment with G-CSF (lenograstim at 263 μg) from day 5 to day 9. The proportion of patients experiencing FN and G4 neutropenia was considered. Results: A total of 36 patient…

AdultMaleNeutropeniaSettore MED/06 - Oncologia MedicaAntineoplastic AgentsSarcomaSoft Tissue Neoplasmslenograstrim sarcoma neutropeniaMiddle AgedLenograstim Febrile Neutropenia Soft tissue sarcomaLenograstimRecombinant ProteinsYoung AdultAdjuvants ImmunologicGranulocyte Colony-Stimulating FactorHumansFemaleIfosfamideAgedEpirubicin
researchProduct

Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter stud…

2012

Recently, the number of studies on male breast cancer (MBC) has been increasing. However, as MBC is a rare disease there are difficulties to undertake studies to identify specific MBC subgroups. At present, it is still largely unknown whether BRCA-related breast cancer (BC) in men may display specific characteristics as it is for BRCA-related BC in women. To investigate the clinical–pathologic features of MBC in association with BRCA mutations we established a collaborative Italian Multicenter Study on MBC with the aim to recruit a large series of MBCs. A total of 382 MBCs, including 50 BRCA carriers, were collected from ten Italian Investigation Centres covering the whole country. In MBC p…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyMolecular subtypesSettore MED/06 - Oncologia MedicaDNA Mutational AnalysisGenes BRCA2Genes BRCA1Breast Neoplasms MaleYoung Adultclinical-pathologic features; brca2; brca1; male breast cancer; molecular subtypesBreast cancerInternal medicinemedicineCarcinomaHumansYoung adultFamily historyskin and connective tissue diseasesBRCA1; BRCA2; Clinical-pathologic features; Male breast cancer; Molecular subtypesAgedAged 80 and overGynecologybusiness.industryCarcinoma Ductal BreastMiddle Agedmedicine.diseaseBRCA1BRCA2Male breast cancerItalyOncologyMale breast cancerImmunohistochemistryOvarian cancerbusinessClinical-pathologic featureRare disease
researchProduct